10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
January 2026 in “Mendeley Data” January 2026 in “Mendeley Data” 7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
Baricitinib helps regrow hair in teens with severe alopecia areata.
29 citations
,
April 2019 in “BMJ. British medical journal” Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
42 citations
,
February 2019 in “Circulation” Targeting ATM could help manage heart cell enlargement due to pressure overload.
October 2021 in “European urology open science”
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
October 2024 in “Frontiers in Oncology” A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.
January 2025 in “International Journal of Advancement in Life Sciences Research” Drug repurposing can be cost-effective but needs more testing for safety and effectiveness.
38 citations
,
January 2020 in “Cell Transplantation” Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.
2 citations
,
April 2024 in “Urology Annals” Taking dutasteride every other day works as well as daily and better preserves sexual function.
2 citations
,
November 2024 in “In Silico Pharmacology”
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
2 citations
,
September 2014 in “International Journal of Dermatology” Sodium valproate can worsen psoriasis-like skin conditions.
19 citations
,
December 2008 in “Arthritis Care & Research” The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
The research developed new fortilin protein constructs for potential heart disease treatments.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
January 2022 in “International Journal of Pharmacognosy and Pharmaceutical Sciences” Semecarpus anacardium Linn. has multiple medicinal benefits, including anti-inflammatory and antioxidant effects.
March 2024 in “Journal of the American Academy of Dermatology” 75 citations
,
August 2005 in “Expert Opinion on Pharmacotherapy” Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.